Download Free Medical Evidence-Based Practices for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome PowerPoint Presentation

Evidence-Based Practices for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Familial Pancreatic Cancer, which is titled "Evidence-Based Practices for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome", to know about hereditary breast and ovarian cancer syndrome (HBOC) and lynch syndrome (LS), and know how to identify individuals at risk and their families.

Tags : Familial Pancreatic Cancer, Evidence-Based Practices, Hereditary, Breast, Ovarian, Cancer, Syndrome, Lynch Syndrome, HBOC, lynch syndrome, LS

Published on : May 18, 2021 | Views : 1949 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Evidence-Based Practices for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome 1
Slide 2-

Overview What are Hereditary Breast and Ovarian Cancer syndrome (HBOC) and Lynch syndrome (LS)? How common are LS and HBOC? How do LS and HBOC affect individuals and families? How do I identify individuals at risk and their families? What should I do after I identify a patient at risk? What should I do after a patient is diagnosed? 2
Slide 3-

Hereditary Breast and Ovarian Cancer Syndrome (HBOC): An Overview Individuals with HBOC have a significantly increased risk for breast, ovarian, and other cancers. Identifying individuals with HBOC is important because steps can be taken to reduce future cancer risks for patients and their relatives. 3
Slide 4-

BRCA-Associated Hereditary Breast and Ovarian Cancer Syndrome Caused by inherited changes in BRCA1 and BRCA2 genes Increased risk for breast, ovarian, and other types of cancer (high grade prostate, male breast, pancreatic) Certain ethnic groups are at increased risk for BRCA mutations 1 in 40 Ashkenazi Jews Interventions can significantly reduce risk of cancers 4
Slide 5-

BRCA1 and BRCA2 Mutations: Cancer Risks by Age 70 U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014;160:271-281. Petrucelli, N., Daly, M.B., and Feldman, G.L. (2013). BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. GeneReviews. Retrieved from: http://www.ncbi.nlm.nih.gov/books/NBK1247/ 5
Slide 6-

Lynch Syndrome: An Overview Individuals with Lynch syndrome have a significantly increased risk for colorectal (colon), endometrial, and other cancers. Identifying individuals with Lynch syndrome is important because steps can be taken to reduce cancer risks in the future for patients and their relatives. 6
Slide 7-

Lynch Syndrome Increased risk for certain cancers: Colorectal Endometrial (Uterine) Ovarian Bladder Stomach Caused by inherited mutations in the mismatch repair genes, MLH1, MSH2, MSH6, and PMS2, and the EPCAM gene Interventions can significantly reduce risk of cancers 1 in 30 patients with colorectal cancer has Lynch Syndrome 7
Slide 8-

Lynch Syndrome: Cancer Risks by Age 70 Source: NCCN http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf 8
Slide 9-

Identifying Patients at Risk for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome 9
Slide 10-

How Do I Identify Patients At Risk for Hereditary Cancer Syndromes? National Evidence-Based Guidelines: Hereditary Breast and Ovarian Cancer U.S. Preventive Services Task Force (USPSTF) Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women (2013) Lynch Syndrome Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genetic Testing Strategies in Newly Diagnosed Individuals with Colorectal Cancer Aimed at Reducing Morbidity and Mortality from Lynch Syndrome (2009) 10
Slide 11-

Hereditary Breast and Ovarian Cancer: U.S. Preventive Services Task Force “The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with one of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2)” “Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing.” U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014;160:271-281. 11
Slide 12-

Hereditary Breast and Ovarian Cancer: Family Health History Risk Assessment ≥1 family member with breast, ovarian, or other BRCA-related cancer Family health history risk stratification tools to determine the need for genetic counseling Tools included in USPSTF recommendation: Ontario Family History Assessment Tool Manchester Scoring System Referral Screening Tool Pedigree Assessment Tool Family History Screen 7 (FHS-7) U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014;160:271-281. 12
Slide 13-

Example: Referral Screening Tool Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med. 2009;11:783-9. 16
Slide 14-

Example: Pedigree Assessment Tool Hoskins KF, Zwaagstra A, Ranz M. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer. 2006;107:1769-76. 14
Slide 15-

Other Clinical Guidelines for Identifying Patients At Risk for HBOC USPSTF: individuals without a personal history of breast or ovarian cancer Individuals with a personal history of breast, ovarian, and other cancers National Comprehensive Cancer Network (NCCN), 2017 American College of Medical Genetics and Genomics (ACMG)/ National Society of Genetic Counselors (NSGC), 2014 15
Slide 16-

National Comprehensive Cancer Network (NCCN) Guidelines (2017) Further genetic evaluation if personal history of Ovarian carcinoma Male breast cancer Pancreatic cancer or high grade prostate cancer at any age, 1 or more of the following: ≥ 1 close blood relatives with: Ovarian carcinoma at any age Breast cancer ≤50 years ≥ 2 close blood relatives with: Breast cancer at any age Pancreatic cancer at any age High grade prostate cancer at any age Pancreatic cancer and Ashkenazi Jewish or Eastern European ancestry BRCA1 or BRCA2 mutation detected by tumor profiling in the absence of germline mutation analysis Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. 16
Slide 17-

National Comprehensive Cancer Network (NCCN) Guidelines (2017) Further genetic evaluation if personal history of breast cancer and one or more of the following Diagnosed ≤ age 45 Diagnosed ≤ age 50 with: Another primary cancer ≥ 1 close blood relative with breast cancer, pancreatic cancer, or high grade prostate cancer at any age An unknown or limited family history Diagnosed ≤ age 60 with triple negative breast cancer Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. 17
Slide 18-

National Comprehensive Cancer Network (NCCN) Guidelines (2017) Further genetic evaluation if personal history of breast cancer and one or more of the following Diagnosed at any age with: ≥ 1 close blood relative with breast cancer diagnosed ≤ age 50 ≥ 2 close blood relatives with breast cancer at any age ≥ 1 close blood relative with ovarian carcinoma ≥ 2 close blood relatives with pancreatic cancer and/or high grade prostate cancer at any age A close male blood relative with breast cancer Ashkenazi Jewish or Eastern European ancestry Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. 18
Slide 19-

ACMG/NSGC Referral Indications for Cancer Predisposition Assessment (2014) Further genetic evaluation if personal history of Breast cancer diagnosed ≤ age 50 Triple-negative breast cancer diagnosed ≤ age 60 Two or more primary breast cancers Ovarian, fallopian tube, or primary peritoneal cancer Male breast cancer Ashkenazi Jewish or Eastern European ancestry and breast or pancreatic cancer at any age Breast, ovarian, or pancreatic cancer and two or more cases of breast, ovarian, pancreatic, or aggressive prostate cancer in close blood relatives Aggressive prostate cancer and two or more cases of breast, ovarian, or pancreatic cancer in close blood relatives Source: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine. 2014 . 19
Slide 20-

Is Your Patient At Risk For HBOC? [sample HBOC risk assessment pedigree] There is a free CME Course Hereditary Breast and Ovarian Cancer, Available at: https://learn.education.jax.org/browse/hpe/cme/courses/hboc Developed by the National Coalition for Health Professional Education in Genetics (NCHPEG), now The Jackson Laboratory Clinical and Continuing Education Program 20
Slide 21-

HBOC Risk Assessment Pedigree SAMPLE 21
Slide 22-

Lynch Syndrome: Evaluation of Genomic Applications in Practice and Prevention Recommendation (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found sufficient evidence to recommend offering [screening and] genetic testing for Lynch syndrome to individuals with newly diagnosed colorectal cancer to reduce morbidity and mortality in relatives. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine 2009; 11:35-41. 22
Slide 23-

Other Clinical Guidelines For Identifying Patients At Risk for Lynch Syndrome EGAPP: individuals with a personal history of colorectal cancer Individuals without a personal history of colorectal cancer National Comprehensive Cancer Network (NCCN), 2016 American College of Medical Genetics (ACMG) and the National Society of Genetic Counselors (NSGC), 2014 23
Slide 24-

National Comprehensive Cancer Network (NCCN) Guidelines (2017): Family History Further genetic evaluation for Women with endometrial cancer diagnosed before age 50 Individuals in families with known Lynch syndrome Individuals with a family history of one or more of the following First-degree relative with colorectal or endometrial cancer diagnosed before age 50 First-degree relative with colorectal or endometrial cancer and another synchronous or metachronous Lynch-syndrome related cancer** Two or more first- or second-degree relatives with Lynch-Syndrome-related cancers**, at least one of whom was diagnosed before age 50 Three or more first- or second-degree relatives with Lynch-Syndrome-related cancers**, regardless if age ** Lynch syndrome associated cancers include colorectal cancer, endometrial (uterine) cancer, gastric cancer, ovarian cancer, pancreatic cancer, ureter and renal pelvis cancers, biliary tract cancer, brain cancer (usually glioblastoma), small intestinal cancer, sebaceous gland adenocarcinoma, and keratoacanthoma Source: National Comprehensive Cancer Network. NCCN Guidelines Version 1.2017 Genetics/Familial High-Risk Assessment: Colon. 24
Slide 25-

ACMG/NSGC (2014) Guidelines: Endometrial Cancer Further genetic evaluation if Endometrial cancer < age 50 Endometrial cancer ≥ age 50 and a first-degree relative with colorectal or endometrial cancer at any age Synchronous or metachronous colorectal or endometrial cancers in the same person Endometrial cancer showing mismatch repair deficiency on tumor screening Endometrial cancer and two additional cases of any LS-associated cancer in the same person or in close relatives All affected relatives must be on the same side of the family Source: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine. 2014 25
Slide 26-

Screening Tumor Tissue for Lynch Syndrome For individuals newly diagnosed with colorectal cancer, tumor screening is often done before genetic testing Less complicated Less expensive Identify patients for genetic testing Guide which genes to include in genetic testing 26
Slide 27-

Screening Tumor Tissue for Lynch Syndrome Immunohistochemistry (IHC) or Microsatellite Instability (MSI) screening Screening tests, not diagnostic tests Identify those more likely to have Lynch syndrome but further testing needed for diagnosis of Lynch syndrome Can be done individually or in combination Some institutions may decide to perform IHC and/or MSI testing on newly diagnosed endometrial cancers Source: National Comprehensive Cancer Network. NCCN Guidelines Version 1.2017 Genetics/Familial High-Risk Assessment: Colon. 27
Slide 28-

Immunohistochemical (IHC) Screening Mutations in mismatch repair genes result in loss of expression of 1-2 of the mismatch repair proteins in tumor tissue IHC involves staining tumor tissue for protein expression of the Lynch syndrome-related mismatch repair genes: MLH1, MSH2, MSH6, and PMS2 Absence of staining in tumor tissue = loss of protein expression If screen positive, referral for genetic counseling and diagnostic germline mutation analysis About 20% CRC tumors have abnormal IHC, not all Lynch 5-15% false-negative rate Not useful screen for other hereditary colon cancer syndromes This tumor sample has absent staining of MLH1 and PMS2 proteins http://www.lynchscreening.net/implementation/immunohistochemistry-ihc-only-2 Source: National Comprehensive Cancer Network. NCCN Guidelines Version 1.2017 Genetics/Familial High-Risk Assessment: Colon. and American Medical Association and National Coalition for Health Professional Education in Genetics. Colorectal Cancer Fact Sheets: Testing for Lynch syndrome. 2012 Feb. 28
Slide 29-

Screening Tumor Tissue for Lynch Syndrome: BRAF Testing BRAF mutations present in 15% of colorectal cancers BRAF mutations can inhibit MLH-1 expression so absent MLH-1 and PMS2 expression in IHC screening could be due to BRAF mutations BRAF mutations are not associated with Lynch syndrome and are consistent with sporadic, not inherited, colorectal cancer Molecular genetic testing for somatic BRAF mutations can help rule out Lynch syndrome in individuals with absent expression of MLH1 and PMS2 in IHC screening For Endometrial Cancers: BRAF testing is not helpful in distinguishing sporadic vs. Lynch syndrome-related cancers Kohlmann W, Gruber SB. Lynch Syndrome. 2004 Feb 5 [Updated 2014 May 22]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1211/ 29
Slide 30-

IHC Testing Algorithm
Slide 31-

Microsatellite Instability (MSI) Testing Compares areas of repeated DNA, called microsatellites, in the tumor tissue to normal tissue to determine if the mismatch repair genes associated with Lynch syndrome are working properly 5-15% false-negative rate Possible results MSI-High (MSI-H): microsatellite unstable, patient may have Lynch syndrome Additional testing to determine if result is due to Lynch syndrome (IHC, MLH1 hypermethylation testing, or DNA testing) MSS (MSI-Low): microsatellite stable, patient likely does not have Lynch syndrome Source: National Comprehensive Cancer Network. NCCN Guidelines Version 1.2017 Genetics/Familial High-Risk Assessment: Colon. and American Medical Association and National Coalition for Health Professional Education in Genetics. Colorectal Cancer Fact Sheets: Testing for Lynch syndrome. 2012 Feb. 31
Slide 32-

Screening Tumor Tissue for Lynch Syndrome > 90% of colorectal cancer tumors due to Lynch syndrome screen positive MSI-High Abnormal IHC results (lack protein expression for one or more of the mismatch repair genes) About 1 in 5 patients who screen positive has Lynch syndrome Genetic testing to identify mutation 32
Slide 33-

Is Your Patient At Risk for LS? [sample LS risk assessment pedigree] Insert Video Clip Here There is a free CME Course Colorectal Cancer: Is Your Patient at High Risk? Available at https://www.jax.org/education-and-learning/clinical-and-continuing-education/cancer-resources/colorectal-cancer-is-your-patient-at-high-risk Developed by the American Medical Association and the National Coalition for Health Professional Education in Genetics (NCHPEG), now The Jackson Laboratory Clinical and Continuing Education Program 33
Slide 34-

Lynch Syndrome Risk Assessment Pedigree SAMPLE 34
Slide 35-

Family Health History Screening and Risk Assessment 35
Slide 36-

Family Health History Screening and Risk Assessment Health care providers should ask the following questions when taking a family health history: Do you have any relatives who have been diagnosed with cancer? Be sure to ask about parents, brothers, sisters, children, grandparents, aunts, uncles, nieces, and nephews For each relative with a diagnosis of cancer What type(s) of cancer did the relative have (note multiple primaries)? What was the specific pathology of the cancer (if known)? Is the tumor available for testing (if colorectal or endometrial cancer)? At what age was the relative diagnosed with cancer? Family ethnicity/country of origin 36
Slide 37-

Possible Indicators for BRCA1/BRCA2 Mutations Personal or family health history of Known BRCA1 or BRCA2 mutation in the family Breast cancer diagnosed ≤ age 45 in women Breast cancer diagnosed ≤ age 50 in women with at least one close blood relative with breast, pancreatic, or high grade prostate cancer at any age or limited family history Triple negative breast cancer diagnosed ≤ age 60 in women Two diagnoses of breast cancer or two types of BRCA-related cancer in the same person Breast cancer at any age in men Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. 37
Slide 38-

Possible Indicators for BRCA1/BRCA2 Mutations Personal or family health history of Breast cancer at any age and any of the following Two or more close blood relative with breast cancer at any age One or more close blood relative with breast cancer diagnosed ≤ age 50 Two or more close blood relatives with pancreatic cancer or high grade prostate cancer Close male blood relative with breast cancer Close blood relative with ovarian carcinoma Ashkenazi Jewish or Eastern European ancestry Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. 38
Slide 39-

Possible Indicators for BRCA1/BRCA2 Mutations Personal or family health history of Ovarian carcinoma Pancreatic cancer and at least 2 close blood relatives with breast, ovarian, pancreatic cancer, or high grade prostate cancer at any age Aggressive prostate cancer and 2 close blood relatives with breast, ovarian, or pancreatic cancer at any age Pancreatic cancer and Ashkenazi Jewish or Eastern European ancestry Third-degree blood relative with breast cancer or ovarian carcinoma who has 2 or more close blood relatives with breast cancer (at least one diagnosed < age 50) or ovarian carcinoma Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. and A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine. 2014 39
Slide 40-

Other Causes of Breast and Ovarian Cancer in a Family Familial cancers Mutations in genes other than BRCA1 or BRCA2 Shared environment Chance clustering of sporadic cancer cases Combinations of these factors Other genes associated with inherited susceptibility to breast and/or ovarian cancer PTEN, TP53, CDH1, ATM, CHEK2, PALB2, STK11 and others Genetic testing using multi-gene panels is available that include these and other genes Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. 40
Slide 41-

Possible Indicators for Lynch Syndrome EGAPP recommends genetic screening of all newly diagnosed patients with colorectal cancer Indicators cited by other guidelines Endometrial (uterine) cancer < age 50 Three or more family members with a Lynch-associated cancer History of a known Lynch syndrome mutation in a family Sebaceous adenomas or carcinomas Abnormal IHC/MSI Source: National Comprehensive Cancer Network. NCCN Guidelines Version 1.2017 Genetics/Familial High-Risk Assessment: Colon. And A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine. 2014 41
Slide 42-

Other Causes of Colorectal Cancer Often sporadic Other familial cancer syndromes APC-associated familial adenomatous polyposis (FAP, also known as classic FAP) Attenuated FAP (AFAP) MUTYH-associated polyposis (MAP) Familial colorectal cancer type X Peutz-Jeghers syndrome Cowden syndrome Juvenile polyposis American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) have separate management guidelines for these syndromes American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk- Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines. Journal of Clinical Oncology. 2014. 58. 1322. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2017 Genetics/Familial High-Risk Assessment: Colon. 42
Slide 43-

Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome 43
Slide 44-

What Do I Do After I Identify a Patient as At-Risk? Refer for genetic counseling Provide education regarding the genetics of cancer and the likelihood of developing cancer Discuss risks, benefits, and limitations of genetic testing Review appropriate cancer screening and prevention strategies NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: J Genet Counsel (2013) 22:155-163. 44
Slide 45-

Who Can Provide Genetic Counseling? Several professional organizations describe skills and training needed for comprehensive genetic counseling National Society of Genetic Counselors American College of Surgeons Commission on Cancer 45
Slide 46-

Who Can Provide Genetic Counseling? National Society of Genetic Counselors Certified Genetic Counselors Have Master’s-level education through accredited program Passed certification exam Meet other requirements of American Board of Genetic Counseling Certification and licensure requirements differ by state Search for a genetic counselor by specialty and location at http://www.nsgc.org/ 46
Slide 47-

Who Can Provide Genetic Counseling? American College of Surgeons Commission on Cancer Standard 2.3. Risk Assessment and Genetic Counseling Genetics professionals include American Board of Genetic Counseling or American Board of Medical Genetics board-certified or licensed genetic counselor American College of Medical Genetics physician board-certified in medical genetics Genetics Clinical Nurse or an Advanced Practice Nurse in Genetics credentialed through Genetics Nursing Credentialing Commission Board-certified physician with experience in cancer genetics (defined as providing cancer risk assessment on a regular basis) Advanced practice oncology nurse with specialized graduate education in cancer genetics and hereditary cancer predisposition syndromes; certification by the Oncology Nursing Certification Corporation preferred Educational seminars offered by commercial laboratories about how to perform genetic testing not considered adequate training for cancer risk assessment and genetic counseling 47
Slide 48-

Why is Genetic Counseling Essential? Ensure full informed consent Address patient’s and families’ concerns Review differential diagnosis Assess best strategy to test the family Obtain records (on other family members), pathology, detailed family health history Interpret results accurately Positive, negative, variant of unknown significance Increase the likelihood that correct surveillance is recommended Coordinate testing for family members 48
Slide 49-

Cascade Screening An active process to find relatives of person affected with certain genetic conditions at a pre-symptomatic stage because interventions exist that can save lives An example of cascade screening for HBOC: 49
Slide 50-

Risks to Family Members BRCA- and Lynch syndrome-associated genetic changes are almost always inherited from a parent First degree relatives (parents, siblings, children) of an individual diagnosed with a BRCA or Lynch syndrome-associated genetic change have a 50% risk of having the same genetic change Second, third, and more distant relatives are also at risk to have the same genetic change Relatives who do not have the genetic change identified in the family cannot pass it on to their children 50
Slide 51-

Genetic Testing in Relatives First person tested in family should have had breast or ovarian cancer (for BRCA testing) or colorectal or other Lynch syndrome-related cancer (for Lynch syndrome testing) whenever possible Full gene sequencing of one or more indicated genes Testing for founder mutations if Ashkenazi Jewish or Eastern European ancestry Identify specific genetic change in the family Relatives should have genetic testing for the specific genetic change identified Single Site testing or Site-specific testing Significantly less expensive 51
Slide 52-

Continuity of Care Continuity of care is essential and includes Continuing contact with patients, inquiring about changes in family history Asking carriers about other family members considering genetic counseling Discuss new testing techniques, changes in variants of uncertain significance 52
Slide 53-

When Can Genetic Evaluation Be Done? After identification of risk (significant family health history) After cancer diagnosis Concomitant with diagnosis and treatment discussions During treatment, including chemotherapy After treatment Months, years later, when other family members become concerned 53
Slide 54-

Affordable Care Act Affordable Care Act (ACA) requires many health plans to provide in-network coverage without cost-sharing for preventive services with a USPSTF rating of “A” or “B” B rating for BRCA screening recommendation Genetic counseling, if appropriate, is covered in-network without cost sharing when used in accordance with the USPSTF recommendation Department of Health and Human Service clarified in 2013 that the BRCA test itself, if appropriate, is within the scope of the USPSTF recommendation and should be covered in-network without cost sharing Applies to non-grandfathered health plans and health insurance coverage offered in the individual or group market *Billing practices for genetic counseling vary by institution and may affect coverage http://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html https://www.healthcare.gov/preventive-care-benefits/women/ 54
Slide 55-

Management Options for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome 55
Slide 56-

Interventions for Women with BRCA1 and BRCA2 Mutations Several management options exist but the strength of evidence varies across types of interventions USPSTF recommends: Risk-reducing bilateral mastectomy 85-100% reduction in breast cancer risk Risk-reducing oophorectomy or bilateral salpingo-oophorectomy (BSO) 69-100% reduction in ovarian cancer risk 37-100% reduction in breast cancer risk Chemoprevention Tamoxifen or raloxifene U.S. Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014;160:271-281. 56
Slide 57-

Interventions for Women with BRCA1 and BRCA2 Mutations Other recommendations include increased surveillance: Breast Breast awareness starting at age 18 Clinical breast exam 2X per year beginning at age 25 Yearly MRI or mammogram (Age 25-29 years) Yearly MRI and mammogram (Age 30-75 years) Ovarian Data do not support routine ovarian screening Not shown to be sufficiently sensitive or specific but may be considered: Trans-vaginal ultrasound starting at age 30-35 Serum CA-125 Source: National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. BRCA-A. 57
Slide 58-

Interventions for Individuals with Lynch Syndrome EGAPP recommends: Contacting blood relatives to offer counseling and targeted testing for Lynch syndrome For relatives with Lynch syndrome, having colonoscopies more frequently and beginning at an earlier age For all women with Lynch syndrome (both index case and relatives), considering additional surveillance for endometrial cancer Not address colorectal cancer treatment in index case Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine 2009; 11:35-41. 58
Slide 59-

Interventions for Individuals with Lynch Syndrome NCCN recommends: Colon and Rectum Colonoscopy every 1-2 years starting at age 20-25 (or 2-5 years prior to age of earliest CRC diagnosis in family if relative diagnosed < age 25) Endometrium and Ovary Patient education that dysfunctional uterine bleeding warrants evaluation Risk-reducing total abdominal hysterectomy-bilateral salpingo-oophorectomy Annual endometrial sampling (not clear evidence to support this screening) Limited screening for ovarian cancer at provider’s discretion (not clear evidence to support this screening) Gastric and Small Bowel Extended duodenoscopy and polypectomy at 3-5 yr. intervals beginning age 30-35 Urinary Tract Annual urine analysis starting at age 30-35 Central Nervous System Cancer Annual physical/neurological exam starting at age 25-30 National Comprehensive Cancer Network. NCCN Guidelines Version 2.2017 Genetics/Familial High-Risk Assessment: Breast and Ovarian. BRCA-A. 59
Slide 60-

Interventions for Individuals with Lynch Syndrome European Society for Medical Oncology/American Society of Clinical Oncology recommends: Colon and Rectum Colonoscopy every 1-2 years starting at age 20-25 or 5 years before the youngest case in the family Endometrium and ovary- Gynecological examination, pelvic ultrasound, CA-125 analysis, and aspiration biopsy every year, starting at ages 30-35 Risk-reducing total abdominal hysterectomy-bilateral salpingo-oophorectomy Gastric cancer- Search for presence of Helicobacter pylori and subsequent eradication Upper gastrointestinal endoscopy every 1-3 years for high incidence populations Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk- Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines. Journal of Clinical Oncology. 2014. 58. 1322. 60
Slide 61-

Bidirectional Cancer Registry Reporting for the Identification of Individuals at Risk for Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome 61
Slide 62-

Cancer Registries All states maintain central cancer registries in accordance with state laws All cancers diagnosed in a state are reported to that state’s central cancer registry Cancer registrars at each institution collect information required by the state to submit to the state registry, including: Demographics Information about cancer diagnosis Treatment information 62
Slide 63-

Cancer Registries State central cancer registry data are used for Identifying trends Public health purposes Approved research Patient information is kept confidential Only reported in aggregate, without patient identifiers IRB approval required for research using cancer registry data 63
Slide 64-

Bidirectional Cancer Registry Reporting Insert Video Clip Here 64
Slide 65-

Bidirectional Cancer Registry Reporting A two-way exchange of information between the state cancer registry and reporting institutions Cancer cases reported to state registry by institution State cancer registry uses national guidelines to identify cases with increased risk for HBOC or LS State compiles these cases and associated informational materials for providers and patients State sends this information back to institution 65
Slide 66-

Information Provided Through Bidirectional Cancer Registry Reporting Number of patients identified as being potential candidates for genetic evaluation for HBOC or LS Information for providers about HBOC and LS Summary of patient management recommendations List of cancer genetic counseling services in the state Patient educational materials about HBOC and LS Information to assist patients with sharing information about their HBOC or LS diagnosis with family members 66
Slide 67-

State Tumor Registry Data for xxxx-xxxx Potential HBOC-Associated Cancers* *These are cancers in individuals who should be evaluated for referral to genetic counseling but are not confirmed HBOC-associated. 67
Slide 68-

State Tumor Registry Data xxxx-xxxx Potential Lynch Syndrome Associated Cancers* *These are cancers in individuals who should be evaluated for referral to genetic counseling but are not confirmed HBOC-associated. 68
Slide 69-

How Bidirectional Cancer Registry Reporting Can Improve Patient Health Identifies patients who are potential candidates for genetic counseling and testing for HBOC and LS Allows for identification of at-risk relatives of individuals with HBOC or LS through cascade screening Provides patients and their family members with information for primary and secondary prevention of cancer in the future, if patients are contacted as part of bidirectional reporting program Aids providers in personalizing screening and prevention plans for patients and their family members, if providers receive information on individual patients Increases awareness of national guidelines for HBOC and LS 69
Slide 70-

[State’s] Bidirectional Cancer Registry Reporting Program [Use this slide to describe the program being implemented in your state. For example, who will be receiving information from the cancer registry and in what format? What patients will be identified? Will providers have access to specific patient names? Etc.] 70
Slide 71-

Bidirectional Cancer Registry Reporting: Limitations Bidirectional reporting will not identify all patients who meet national guidelines Most state cancer registries do not collect family history information, so patients with a significant family history of cancer may not be identified. Providers must continue to be vigilant in identifying these patients through careful family health history collection. Lag in registry data (2+ years) so most individuals will be finished with treatment at the time they are identified. Reporting physician information is not always reliable, and provider may no longer provide care for patient. Reporting institution might be where patient got diagnosed and not where they received care or routinely see doctors. Reports sent to institutions may not be seen by providers. 71
Slide 72-

Information for Patients and Families
Slide 73-

Brochure Talking to Your Family About Your Diagnosis of Lynch Syndrome When you share information with people, sometimes they feel helpless and don’t want to address it. I used to have that mentality, too. After my genetic testing, the genetic counselor asked if I wanted to come in to talk about my test results or if I would rather have them over the phone. I wanted it quick like a band-aid. At that moment, my life changed: I was positive for Lynch syndrome. I could not ignore it anymore. Now there’s always the question, where do you go from here? Because it’s not something you get better from. That is the most difficult part of explaining to people what Lynch syndrome is and what it means for the future. Why Talk to My Family? Your family members can benefit from knowing about your diagnosis of Lynch syndrome. Talk to your family members about Lynch syndrome, so that they will know that: Lynch syndrome is passed through families. A person with Lynch syndrome is more likely to get colorectal, endometrial (uterine), ovarian, and other cancers. Genetic counseling and testing for Lynch syndrome can provide information about their risk. If they choose to be tested, they should be tested for the same mutation that you have. Steps can be taken to prevent colorectal and other cancers or find them earlier. IT’S NOT EASY... ...but talking about Lynch syndrome is one of the most important things you can do to protect your family. Judi’s Story Insert Your Logo/Organization Info Here
Slide 74-

What if My Family Does Not Want to Talk? Talking to some family members about Lynch syndrome might not be easy. Some might not understand why they need to know this information. Others might be nervous about receiving a diagnosis of Lynch syndrome. Remember that family members need to make their own choices about getting tested, whether or not you agree with their decisions. If family members don’t want to talk about Lynch syndrome, respect their wishes. Let them know you are available to talk if they have questions, and give them places to find information. When family members do not want to talk about Lynch syndrome, you might feel upset or alone. Seek support from friends, healthcare providers, other family members, or people you know with Lynch syndrome. Where Can I Find More Information? You can find more information on Lynch syndrome at: www.ghr.nlm.nih.gov/condition/lynch-syndrome You can find information on support groups for Lynch syndrome at: http://www.diseaseinfosearch.org/Lynch+syndrome/3371 How Do I Talk to My Family About My Lynch Syndrome Diagnosis? WHO: Your parents, siblings, and children are the family members who are most likely to have Lynch syndrome. Other blood relatives, such as aunts, uncles, nieces, nephews and cousins, are also more likely to have Lynch syndrome. Your healthcare provider or genetic counselor can help you figure out who in your family might have Lynch syndrome and thus would benefit from knowing about your diagnosis. WHAT: You can share test results, letters from your doctor or genetic counselor, or other information you received about your diagnosis with your family. Giving family members information about your specific genetic mutation helps their healthcare providers know exactly which test to use and might possibly save your family money. HOW: If you need extra support talking to your family, bring a friend. You can also ask a family member to attend your next medical appointment with you. The website http://kintalk.org can help you let your relatives know about your diagnosis and provides resources to help them learn more about Lynch syndrome. A sample letter that you can fill out and send to your family is available at www.cdc.gov/genomics/restoflink How Do I Talk to My Children? If you have Lynch syndrome, each of your children has a 50% (1 in 2) chance of having Lynch syndrome. Genetic testing for Lynch syndrome is typically not recommended for children younger than 18, but can be considered when your children reach adulthood. Younger children might not be able to understand what your diagnosis means for you or for them. Children differ in the age at which they are ready to learn about this information. Answer the questions they ask. They will ask more complex questions as they grow and are ready to learn more. Know that your children may have fears about the risk both to themselves and to you. Just as you need time and support to cope with the information and accept it, so will your children. Brochure 2
Slide 75-

Information for Providers
Slide 76-

Reporting Tools Reporting tools Sample data report PowerPoint slide set for outreach to providers and institutions (in preparation) In some states, genetic counselors have presented at Grand Rounds to educate providers about hereditary cancers
Slide 77-

Quiz time! 77
Slide 78-

HBOC Scenarios Scenario 1: All adult women diagnosed with breast cancer should be referred for further genetic evaluation True False 78
Slide 79-

HBOC Scenarios Scenario 1: All adult women diagnosed with breast cancer should be referred for further genetic evaluation True False 79
Slide 80-

USPSTF Scenarios Scenario 2: All adult women with a family history of breast cancer should be referred for further genetic evaluation. True False 80
Slide 81-

HBOC Scenarios Scenario 2: All adult women with a family history of breast cancer should be referred for further genetic evaluation. True False 81
Slide 82-

HBOC Scenarios Scenario 3: Any adult woman with multiple primary breast cancers should be referred for further genetic evaluation. True False 82
Slide 83-

HBOC Scenarios Scenario 3: Any adult woman with multiple primary breast cancers should be referred for further genetic evaluation. True False 83
Slide 84-

HBOC Scenarios Scenario 4: Your patient, Karen, was recently diagnosed with breast cancer. Her mother died of breast cancer that was diagnosed at age 65 and her mother’s sister was diagnosed with breast cancer at age 58 and is still living. Because so many people in her family have been affected by breast cancer, she is concerned about the risks for her younger sisters and asks if there is anything she can do to help them. Karen should be referred for further genetic evaluation. True False 84
Slide 85-

HBOC Scenarios Scenario 4: Your patient, Karen, was recently diagnosed with breast cancer. Her mother died of breast cancer that was diagnosed at age 65 and her mother’s sister was diagnosed with breast cancer at age 58 and is still living. Because so many people in her family have been affected by breast cancer, she is concerned about the risks for her younger sisters and asks if there is anything she can do to help them. Karen should be referred for further genetic evaluation. True False 85
Slide 86-

HBOC Scenarios Scenario 5: Your patient, Kristen, has no personal history of cancer. However, her paternal first cousin, Tara, was recently diagnosed with breast cancer and underwent genetic testing. Tara was found to be a carrier of a BRCA2 mutation. Kristen’s father and Tara’s parents have passed away, so they are not available for genetic testing. Kristen should be referred for further genetic evaluation. True False 86
Slide 87-

HBOC Scenarios Scenario 5: Your patient, Kristen, has no personal history of cancer. However, her paternal first cousin, Tara, was recently diagnosed with breast cancer and underwent genetic testing. Tara was found to be a carrier of a BRCA2 mutation. Kristen’s father and Tara’s parents have passed away, so they are not available for genetic testing. Kristen should be referred for further genetic evaluation. True False 87
Slide 88-

HBOC Scenarios Scenario 6: Your patient, Alice, has never had cancer, but her sister, Nina, got breast cancer at age 40. Nina is not interested in getting genetic testing, so Alice decided to get BRCA testing herself, and her test results were negative. This means that Alice is not at an increased risk for breast cancer. a. True b. False 88
Slide 89-

HBOC Scenarios Scenario 6: Your patient, Alice, has never had cancer, but her sister, Nina, got breast cancer at age 40. Nina is not interested in getting genetic testing, so Alice decided to get BRCA testing herself, and her test results were negative. This means that Alice is not at an increased risk for breast cancer. a. True b. False 89
Slide 90-

HBOC Scenarios Scenario 7: Your patient, Megan, has been diagnosed with triple negative breast cancer at age 65. No one else in her family has ever been diagnosed with breast or ovarian cancer, but Megan has four daughters and is worried about their risk for breast cancer. Despite her concerns, Megan should not be referred for further genetic evaluation. True False 90
Slide 91-

HBOC Scenarios Scenario 7: Your patient, Megan, has been diagnosed with triple negative breast cancer at age 65. No one else in her family has ever been diagnosed with breast or ovarian cancer, but Megan has four daughters and is worried about their risk for breast cancer. Despite her concerns, Megan does not meet the criteria for further genetic evaluation. True False 91
Slide 92-

Lynch Syndrome Scenarios Scenario 1: All colorectal cancers should be screened for Lynch syndrome. True False 92
Slide 93-

Lynch Syndrome Scenarios Scenario 1: All colorectal cancers should be screened for Lynch syndrome. True False 93
Slide 94-

Lynch Syndrome Scenarios Scenario 2: Any adult woman diagnosed with endometrial cancer prior to age 50 should be referred for genetic evaluation. True False 94
Slide 95-

Lynch Syndrome Scenarios Scenario 2: Any adult woman diagnosed with endometrial cancer prior to age 50 should be referred for genetic evaluation. True False 95
Slide 96-

Lynch Syndrome Scenarios Scenario 3: An adult male with colorectal cancer and normal IHC screening results should be referred for genetic evaluation. True False 96
Slide 97-

Lynch Syndrome Scenarios Scenario 3: An adult male with colorectal cancer and normal IHC screening results should be referred for genetic evaluation. True False: unless there is a significant family history or other reasons to remain concerned about a hereditary colorectal cancer syndrome (remember 5-10% of IHC screening results are false negatives) 97
Slide 98-

Lynch Syndrome Scenarios Scenario 4: Your patient, Alan, has never had cancer, but has a family history of endometrial and colon cancer. Alan’s maternal grandmother was diagnosed with endometrial cancer at age 66 and his paternal uncle was diagnosed with colon cancer at age 61. Based on his family history, Alan should be referred for further genetic evaluation. True False 98
Slide 99-

Lynch Syndrome Scenarios Scenario 4: Your patient, Alan, has never had cancer, but has a family history of endometrial and colon cancer. Alan’s maternal grandmother was diagnosed with endometrial cancer at age 66 and his paternal uncle was diagnosed with colon cancer at age 61. Based on his family history, Alan should be referred for further genetic evaluation. True False 99
Slide 100-

Lynch Syndrome Scenarios 100 Scenario 5: Your patient, Joe, has never had cancer, but is concerned about his risk for developing cancer due to his family history. His maternal uncle was diagnosed with colon cancer, and his maternal aunt was diagnosed with endometrial cancer. Additionally, his maternal grandmother was diagnosed with ovarian cancer. Joe has heard a lot about inherited cancer on the news and is interested in learning more about it. Based on his family history, Joe should be referred for further genetic evaluation. True False
Slide 101-

Lynch Syndrome Scenarios Scenario 5: Your patient, Joe, has never had cancer, but is concerned about his risk for developing cancer due to his family history. His maternal uncle was diagnosed with colon cancer, and his maternal aunt was diagnosed with endometrial cancer. Additionally, his maternal grandmother was diagnosed with ovarian cancer. Joe has heard a lot about inherited cancer on the news and is interested in learning more about it. Based on his family history, Joe should be referred for further genetic evaluation. True False 101
Slide 102-

Summary Use the evidence-based recommendations for cancer risk assessment and genetic testing for hereditary cancer syndromes to help ensure that your patients receive the life-saving interventions that they need. 102
Slide 103-

Contact Information Presenter contact info State public health department contact info 103 Last Updated: 5/19/2021
Slide 104-

ppt slide no 104 content not found